Lymphoma Clinical Trials in Detroit

Showing 581-600 of 641 trials

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

NCT00005579

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with indolent lymphoma, Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia.

LeukemiaLymphoma

University of VermontStarted Jun 1998

Baltimore, Maryland, United States • Detroit, Michigan, United States • Columbus, Ohio, United States +1 more locations

COMPLETEDPhase 2< 1 mile

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

NCT00045539

RATIONALE: Drugs used in chemotherapy, such as methotrexate and thiotepa, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining methotrexate with thiotepa in treating patients who have newly-diagnosed primary CNS lymphoma.

Lymphoma

New Approaches to Brain Tumor Therapy ConsortiumStarted Oct 2002

Birmingham, Alabama, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +6 more locations

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Lymphoma Trials in Other Cities

Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation

506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Aminocamptothecin in Treating Patients With T-cell Lymphoma

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

Other Conditions in Detroit